Drugs / Dual-target CAR-NK cell product
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07480954 | Feb 2026 → Feb 2027 expected | fallopian tube carcinoma, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dual-target CAR-NK cell product | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07480954 ↗ |
| Modality | Cell therapy | “dual-targeting chimeric antigen receptor natural killer (CAR-NK) cells” NCT07480954 ↗ |
| Target | FOLR1 | “Dual-target CAR-NK cells recognizing Mesothelin (MSLN) and Folate Receptor alpha (FRalpha/FOLR1).” NCT07480954 ↗ |
| Target | MSLN | “Dual-target CAR-NK cells recognizing Mesothelin (MSLN) and Folate Receptor alpha (FRalpha/FOLR1).” NCT07480954 ↗ |
| Target | MUC16 | “Dual-target CAR-NK cells recognizing Mesothelin (MSLN) and MUC16 (CA 125).” NCT07480954 ↗ |